# KOREA Study (Korea Osimertinib Real World Evidence Study to Assess Safety and Efficacy)

> **NCT02777567** · — · COMPLETED · sponsor: **AstraZeneca** · enrollment: 315 (actual)

## Conditions studied

- Non-Small Cell Lung Cancer

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT02777567
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2016-09-29
- **Primary completion:** 2020-03-19
- **Final completion:** 2020-03-19
- **Target enrollment:** 315 (ACTUAL)
- **Last updated:** 2020-09-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02777567

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02777567, "KOREA Study (Korea Osimertinib Real World Evidence Study to Assess Safety and Efficacy)". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT02777567. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*